Topic: Quality incentives durability and payer willingness
Key points:
Small favorable impact in Q2 from 2024 performance; quality program is a core strength.
Year 2+ markets have star ratings at or above 4.25.
Payers are "more willing than ever" to put dollars at risk in quality programs due to their own quality challenges; dollars available for quality scores have stepped up.
Expect quality incentive dollars to increase from 2025 to 2026, magnitude uncertain.
Mgmt stance: Bullish — quality is a durable value driver that aligns payer interests and rewards AGL’s strong performance.
Q7 — Craig Jones
Topic: Potential margin from full adoption of quality incentives
Key points:
Majority of contracts already have quality programs; the change is that dollars are escalating.
Public payers’ own quality challenges have cost them returns, leading them to put more dollars into incentive programs.
No specific margin estimate provided; consistent with prior dynamics.
Mgmt stance: Bullish — escalating dollars play to AGL’s strength, even without full contract renewal.
Q8 — Jack Garner Slevin
Topic: Turnaround timing, portfolio decisions, and ACO REACH
Key points:
Main turnaround pillars unchanged; need to reduce time from performance evaluation to action.
Enhanced data model ties financial outcomes to operational metrics; operating cost review is ongoing but enhanced.
Payer bidding and final 2026 Medicare Advantage rates are major components; market exits/portfolio sizing decisions will come later in the year.
ACO REACH performance in line with expectations; prior $35M–$40M EBITDA contribution guidance is not updated in this Q&A.
Mgmt stance: Neutral — progress on levers but key decisions deferred to later in the year; REACH tracking as expected.
Q9 — George Robert Hill
Topic: Extrapolating data model from 72% of book to remainder
Key points:
No extrapolation was recorded because of variability among payers regarding the adjustment.
Waiting for data from payers where information is not yet available.
Mgmt stance: Cautious — avoided extrapolation due to payer-specific variability.
Q10 — Jeffrey Alan Schwaneke
Topic: 2026 outlook and key drivers
Key points:
No 2025 guidance provided; 2026 final rate notice is a positive start if cost trends stay at ~6% (first-half 2025 level).
Net lift expected from risk adjustment in 2025 and 2024 after v28 impact.
50% of 2026 contracts open for renewal, seeking improved terms; Part D carve-out below 30% and progressing.
Payer bids broadly stable to favorable; lower supplemental benefit underwriting risk due to decreased benefits and more payer information.
Operating expense optimization underway; medical cost trends remain a big question mark.
Mgmt stance: Neutral/positive — multiple controllable levers in place, but macro medical cost trend uncertainty caps enthusiasm.
Q&A Batch (11-14 of 14)
Q11 — Andrew Mok
Topic: Risk adjustment revenue shortfall and cost trend clarification
Key points:
Burden of illness assessments from last year did not yield expected risk adjustment revenue for 2024 and 2025.
Shortfall was due to failure to identify patient conditions and enroll them in appropriate care, not CMS code rejection.
New clinical programs (heart failure, COPD, dementia) were implemented late last year or this year to address this.
First-half cost trend was in line with expectations; prior full-year guidance was 5.3%, but quarterly breakdown was not provided.
Mgmt stance: Neutral; acknowledges underperformance in risk adjustment but points to new programs as corrective actions.
Q12 — Jenny Shen
Topic: Cost trend details and utilization pressure points
Key points:
First quarter had a high percentage of paid claims.
Pressure points: inpatient costs and Part B drugs (specifically oncology), consistent from last year into Q1.
Mgmt stance: Neutral; identifies specific cost drivers without signaling a change in outlook.
Q13 — Lance Arthur Wilkes
Topic: Practice partnerships, other medical expenses, and management structure
Key points:
Partners are predominantly large, long-standing primary care groups in their markets.
Focus on clinical pathway improvement and evidence-based elimination of variability deepens relationships.
Market president and medical director work regularly with partners in each market.
Other medical expense variability is due to partner share calculations on a partner-by-partner basis.
Mgmt stance: Bullish; emphasizes long-term arrangements and clinical focus as stabilizing factors.
Q14 — Lisa Christine Gill
Topic: Cash balance and liquidity through 2026
Key points:
Ended quarter with $327 million in cash and marketable securities.
$176 million off-balance sheet cash held by ACO entities, expected to drop to ~$40 million over next couple of quarters.
Current liquidity provides flexibility to navigate challenging environment.
Confident enough cash to get through 2026, excluding any near-term cash flow improvement actions.
Mgmt stance: Bullish; states sufficient liquidity and confidence in cash runway.